Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Southwest Oncology Group study

Investigational New Drugs

Volumn 16, Issue 3, 1998, Pages 271-274

  Samlowski, Wolfram E ^a   Lew, Danika ^b   Kuebler, Philip J ^c   Kolodziej, Michael A ^d   Medina, Jesus E ^d   Mangan, Kenneth F ^e   Moore Jr , Dennis F ^f   Schuller, David E ^g   Ensley, John F ^h  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c Columbus CCOP ^*  (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e TEMPLE UNIVERSITY   (United States)

^f Witchita CCOP   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

Author keywords

Squamous cell carcinoma; Tomudex

Indexed keywords

RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; VOMITING;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; SURVIVAL ANALYSIS; THIOPHENES;

EID: 0032431383     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006178808095     Document Type: Article

References (9)

1. Schantz SP, Harrison LB, Forastiere AA: Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity and oropharynx. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, Lippincott-Raven, 1997, pp 741-803
2. Kish JA, Weaver A, Jacobs J, Cummings G, Al-Sarraf M: Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 53: 1819-1824, 1984
3. Jacobs C, Lyman G, Velez Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L et al.: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257-263, 1992
4. Forestiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish J, McClure S, Von Feldt E, Williamson SK, Von Hoff DD: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 10: 1245-1251, 1992
5. Tapazoglou E, Kish J, Ensley J, Al-Sarraf M: The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer. Cancer 57: 1105-1109, 1986
6. Dev IK, Dallas WS, Ferone R, Hanlon M, McKee DD, Yates BB: Mode of binding of folate analogs to thymidylate synthase. Evidence for two asymmetric but interactive substrate binding sites. J Biol Chem 269: 1873-1882, 1994
7. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51: 5579-5586, 1991
8. Gibson W, Bisset GM, Marsham PR, Kelland LR, Judson IR, Jackman AL: The measurement of polyglutamate metabolites of the thymidylate synthetase inhibitor, ICI D1694, in mouse and human cultured cells. Biochem Pharmacol 45: 863-869, 1993
9. Yin MB, Guimaraes MA, Zhang ZG, Arredondo MA, Rustum YM: Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor. Cancer Res 52: 5900-5905, 1992